Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.
The prediction market platform says the move will allow investors to isolate binary events like drug approvals from a company’s overall stock performance. Kalshi launched 13 new biotech contracts last night in partnership with AI-powered intelligence firm AppliedXL, including bets on whether US regulators will approve medicines made by companies like Sanofi and Gilead Sciences Inc.